Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 88.5% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 88.5% YoY) and the FY2025 annual result came in at $7.0 million, down 60.52% from the prior year.
• Other Non-Current Liabilities fell to $1.9 million in Q1 2026, from $7.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $17.8 million in Q4 2024 to a low of $25000.0 in Q4 2022.
• A 5-year average of $7.5 million and a median of $6.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 90485.71% in 2022, down 93.43% in 2022.
• Tracing ZVRA's Other Non-Current Liabilities over 5 years: stood at $25000.0 in 2022, then soared by 64300.0% to $16.1 million in 2023, then climbed by 10.58% to $17.8 million in 2024, then tumbled by 60.52% to $7.0 million in 2025, then sank by 73.55% to $1.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.9 million (Q1 2026), $7.0 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.